Evidence map›Paper›PMID 41614492›Full record

Trial reportEuropean stroke journal2026

Randomised, controlled Trial of CT perfusion and angiography compared to CT alone in thrombolysis-eligible acute ischaemic stroke patients: The penumbra and recanalisation acute computed tomography in ischaemic stroke evaluation (PRACTISE) trial.

Keith W Muir, Salwa El Tawil, Alex McConnachie, Ian Ford, Grant Mair, Jattinder Khaira, Kausik Chatterjee, Laszlo Sztriha, Omid Halse, Ibrahim Balogun and 4 more

Abstract readRandomized Controlled TrialMulticenter StudyComparative Study
In one paragraph

Trial report in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Keith W MuirSchool of Cardiovascular & Metabolic Health, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, Scotland, UK.ORCID 0000-0001-9535-022X
Salwa El TawilSchool of Cardiovascular & Metabolic Health, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, Scotland, UK.
Alex McConnachieRobertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, UK.
Ian FordRobertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, UK.
Grant MairCentre for Clinical Brain Sciences and Edinburgh Imaging, University of Edinburgh, Edinburgh, UK.
Jattinder KhairaUniversity Hospitals Birmingham, Birmingham, England UK.
Kausik ChatterjeeCountess of Chester Hospital, Chester, Cheshire West, Chester, UK.
Laszlo SztrihaKing's College Hospital, London, UK.
Omid HalseCharing Cross Hospital, London, UK.
Ibrahim BalogunKent and Canterbury Hospital, Canterbury, Ashford, Kent, UK.
Sanjeev NayakRoyal Stoke University Hospital, Stoke-on-Trent, Staffordshire, UK.
Phil WhiteTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Elizabeth A WarburtonUniversity of Cambridge, Cambridge, Cambridgeshire, UK.
Joanna WardlawCentre for Clinical Brain Sciences and Edinburgh Imaging, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-9812-6642

Funding

Efficacy and Mechanism Evaluation Programme 11/100/78
6 · The paper itself

Abstract

introductionThe role of CT angiography (CTA) and CT perfusion (CTP) in patient selection for thrombolysis <4.5 h after onset is unclear. Additional imaging may improve specificity of diagnosis by excluding stroke mimics or those without salvageable tissue, but may delay treatment. PATIENTS AND

methodsIn a multicentre prospective randomised trial, thrombolysis-eligible patients <4.5 h from symptom onset were randomised 1:1 to non-contrast CT (NCCT) or multimodal CT (NCCT + CTA + CTP). The primary endpoint was the proportion receiving thrombolysis. Secondary end-points were times to decision-making and treatment delivery, early neurological recovery, functional recovery at 3 months and incidence of symptomatic intracerebral haemorrhage (SICH).

resultsBetween March 2015 and May 2018, 271 patients were randomised, 134 to multimodal CT and 137 to NCCT. After initial NCCT, 114 had no contraindication to thrombolysis in the multimodal CT group and 108 in the NCCT group. Mean age was 67.5 years and median NIHSS score was 6 (interquartile range 3-12). Fewer patients assigned multimodal CT received thrombolysis (56/114, 49.1%) compared to NCCT (73/108, 67.6%, adjusted odds ratio (aOR) 0.46 (95% CI: 0.25-0.83), p = 0.0102). Times to treatment decision or thrombolytic administration, early neurological recovery and day 90 functional outcome did not differ significantly. SICH occurred in two patients, both assigned NCCT. Mortality was 6/114 (5.3%) in the multimodal CT group compared to 11/108 (10.2%; aOR 0.46 (95% CI: 0.16, 1.31), p = 0.147) in the NCCT group. DISCUSSION: Despite fewer patients receiving thrombolysis after multimodal imaging, treatment decision times and clinical outcomes did not differ significantly. Multimodal CT may identify patients who do not require thrombolysis such as stroke mimics and non-disabling strokes.

conclusionAmong acute stroke patients imaged <4.5 h from symptom onset, multimodal CT reduced use of thrombolysis. Treatment decision times and clinical outcomes did not differ between groups.

Indexed as

Cerebral AngiographyComputed Tomography AngiographyIschemic StrokeThrombolytic TherapyTomography, X-Ray ComputedAgedFemaleFibrinolytic AgentsHumansMaleMiddle AgedProspective StudiesTreatment OutcomeFibrinolytic Agentsangiographycomputed tomographyimagingischaemic strokeperfusionStrokethrombolysis

Identifiers

PMID41614492
PMCPMC12866261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.